Background Availability of clinical trials for prostate cancer in the US varies greatly by region. County-level analyses are vital to characterize healthcare access, disease burden, and population-level disparities. Methods Utilizing the ClinicalTrials.gov trial database, we collated all interventional prostate cancer...
Vitor Abreu de Góes, Benjamin D. Mercier, Yu-Jun Li et al.· Frontiers in Oncology· 0 citations
276
Background:
Patients receiving immunotherapy frequently experience cancer-related fatigue, symptom burden, and impaired health-related quality of life (HRQOL). Although exercise can improve patient-reported outcomes, the mechanisms underlying its effects remain unclear; this study evaluated whether reductio...
P. G. Bergerot, C. Bergerot, P. W. Schorn et al.· JCO Oncology Practice· 0 citations
Abstract Background For patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have relapsed after anti-programmed death protein 1 (anti–PD-1) or anti-programmed death ligand-1 (anti–PD-L1) treatment, second-line treatment options remain limited, consisting primarily of tyrosine kinase inhibit...
T. Choueiri, S. Pal, R. McKay et al.· The Oncologist· 0 citations
The gut microbiome is increasingly recognised as a clinically modifiable determinant of efficacy and toxicity across systemic cancer therapies, with the most mature evidence in patients receiving immune checkpoint inhibitors (ICIs). The composition and function of intestinal microbes can influence treatment outcomes by...
A. Moradi, R. Winayak, S. Pal· The Lancet Oncology· 0 citations
BACKGROUND
Malignancies arising in young adults often exhibit biological and clinical behaviors distinct from those in older patients. Limited data exist on the prognostic impact of age in metastatic non-clear cell renal cell carcinoma (mnccRCC). This study compared survival outcomes by age using the large-scale TriNet...
A. Cigliola, Nazli Dizman, C. Mercinelli et al.· Clinical Genitourinary Cance...· 0 citations
This analysis compares somatic, germline, immune, transcriptomic, and clinical features of eoRCC vs. typical-onset RCC (toRCC) using a multi-omic real-world dataset and reveals upregulation of hypoxia- and VEGFR-signaling pathways in early-onset ccRCC.
H. Ebrahimi, S. Haake, M. Weitz et al.· The Oncologist· 0 citations
Abstract Background Renal cell carcinoma (RCC) is characterized by an immunogenic tumor microenvironment and frequent activation of angiogenic pathways. Therefore, combining immune checkpoint blockade with VEGF pathway inhibition is a rational therapeutic approach. PF‑08634404 is an investigational anti–PD‑1 and anti‑V...
T. Choueiri, S. Pal, T. Powles et al.· The Oncologist· 0 citations
The TRAVERSE trial demonstrates proof of concept for the role of allogeneic CAR T-cell therapy in solid tumors and had manageable safety and encouraging antitumor activity in CD70-positive ccRCC.
S. Srour, J. Chahoud, A. Drakaki et al.· Journal of Clinical Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
